Introduction {#sec1-1}
============

Colon cancers, as part of the colorectal cancer (CRC) spectrum, have a low prevalence, low incidence and relatively stable rates in India as compared to the West and even other countries in Asia, where rising incidence rates have been noted.\[[@ref1][@ref2][@ref3][@ref4]\] It is not among the five most common incident or prevalent cancers across most rural or urban, population-based or hospital-based registries in India.\[[@ref5]\] Whether this is a reflection of varying diet patterns, lesser outreach of registries or different socioeconomic factors as compared to other parts of the world remains to be seen.\[[@ref4][@ref6]\]

Major improvements in disease-free survival and overall survival (OS) in patients with nonmetastatic colon cancer has been as a result of improving quality of surgery and adjuvant chemotherapy.\[[@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13]\] The importance of microsatellite instability (MSI) status in Stage II cancers, the potentially debilitating neuropathy related to oxaliplatin as well as the arguably benefit of oxaliplatin in patients \>70 years of age, have all lead to a greater role of personalized adjuvant treatment of colon cancers.\[[@ref14][@ref15][@ref16][@ref17]\] The results of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project have also given options to treating oncologists with regard to the duration of adjuvant chemotherapy.\[[@ref18][@ref19]\]

Our institution is a tertiary cancer center in India where approximately 700 CRC patients undergo baseline evaluation and further management.\[[@ref20]\] Previous data have suggested certain unique characteristics of patients diagnosed with colon cancer in India, specifically with relation to age (median age of presentation- 4^th^--5^th^ decades) as well as a higher incidence of signet-ring cancers.\[[@ref21][@ref22]\] With these aspects in mind, we retrospectively evaluated patients with Stage I--III colon cancers for outcomes, with a specific emphasis on the practice of adjuvant chemotherapy.

Materials and Methods {#sec1-2}
=====================

Patient selection {#sec2-1}
-----------------

The study is a retrospective analysis of operated patients who underwent upfront curative intent resection for nonrectal colon cancers from January 2013 to December 2016 at the Department of GI Oncology, Tata Memorial Hospital (TMH), in Mumbai. These patients were extracted from a prospectively maintained colon cancer database at TMH. Patients included in the study satisfied the following criteria-

Adenocarcinoma of the colon, either by presurgical colonoscopic biopsy or postsurgical histopathological reportNo evidence of metastatic disease, either radiologically or intraoperatively.

Patient data which was not included for analysis were:

Operated patients with rectal cancerPatients who received neoadjuvant therapy before surgery of colonic primary.

Details collected and evaluated were preoperative carcinoembryonic antigen levels, site of primary (left, right, etc.), stage (as per AJCC 7^th^ edition), the degree of differentiation, signet-ring morphology, mucinous features, the presence of obstruction and/or perforation, the presence of lymphovascular emboli and/or perineural invasion. These factors were also were evaluated as prognostic factors with additional factors evaluated being age (\<50 years and age \>65 years), delay in administration of adjuvant chemotherapy (≤3 weeks vs. \>3 weeks; ≤4 weeks vs. \>4 weeks; ≤6 weeks vs. \>6 weeks) and presence or absence of cardiovascular abnormalities.

Adjuvant chemotherapy {#sec2-2}
---------------------

The specifics of regimen administered, chemotherapy compliance, completion rates, and requirement of dose reduction was detailed. Planned therapy for patients receiving 5 -- fluorouracil and mFOLFOX-7 was considered as 12, while it was considered as 8 for patients receiving capecitabine or capecitabine-oxaliplatin (CAPOX). The doses for these regimens were as follows:

Modified CAPOX -- Oxaliplatin (130 mg/m^2^ IV on day 1) every 3 weeks plus capecitabine (2000 mg/m^2^/day in two divided doses for 14 days on, 7 days off)Modified FOLFOX-7 -- Oxaliplatin (85 mg/m^2^ IV on day 1), Leukovorin (l-LV) 400 mg IV and 5-FU 2400 mg/m^2^ IV over 46 h (days 1--2) continuous intravenous infusion, every 2 weeksSingle-agent capecitabine -- 2000 mg/m2/day in two divided doses for 14 days on, 7 days off, every 3 weeksSingle-agent 5-FU/LV -- (l-LV) 400 mg IV and 5-FU 2400 mg/m^2^ IV over 46 h (days 1--2) continuous intravenous infusion, every 2 weeks.

As per institution protocols, adverse events were recorded as per NCI-- CTCAE National Cancer Institute - Common Terminology Criteria for Adverse Events version 4.03 in this study.

Clinical data collection and statistics {#sec2-3}
---------------------------------------

For this study demographic data and baseline clinical and tumor characteristics, chemotherapy regimens, surgical procedures, and outcomes were collected retrospectively from the charts maintained prospectively (GI Medical Oncology Information System and electronic medical record system). All data were entered in SPSS (Statistical Package for the Social Sciences) software Version 21 (IBM) and used for analysis. Descriptive statistics including median, frequency, and percentage for categorical variables is used to describe age, gender distribution, and adjuvant treatment. Survival outcomes in terms of event-free survival (EFS) and OS were analyzed. Median EFS was calculated from the date of diagnosis to the date of clinical or radiological evidence of disease recurrence or the last follow-up date. Median OS was calculated from the date of diagnosis until the last follow-up or death. Survival analysis was performed using Kaplan--Meier estimates and log-rank test for bivariate comparisons. All prognostic factors that approached significance on univariate analysis (*P* ≤ 0.05) were considered for multivariate analysis and reported with hazard ratios and 95% confidence intervals. Factors not approaching prespecified *P* ≤ 0.05 value are not reported.

Results {#sec1-3}
=======

Baseline characteristics {#sec2-4}
------------------------

A total of 491 patients satisfied the inclusion criteria for entry into the study. The mean duration between surgery and beginning of adjuvant chemotherapy was 25 days (range: 11--94) \[[Table 1](#T1){ref-type="table"}\].

###### 

Demographic and baseline characteristics

  Characteristic                                                                                       *n* (percentage where applicable)
  ---------------------------------------------------------------------------------------------------- -----------------------------------
  Median age (years)                                                                                   53 (17-87)
  Young age (years)                                                                                    
   Age≤50                                                                                              209 (42.6)
   Age\>50                                                                                             282 (57.4)
  Elderly age (years)                                                                                  
   Age\>65                                                                                             81 (16.5)
   Age≤65                                                                                              410 (83.5)
  Gender                                                                                               
   Male                                                                                                328 (66.8)
   Female                                                                                              163 (33.2)
  Comorbidities                                                                                        
   Hypertension                                                                                        93 (18.9)
   Diabetes mellitus                                                                                   84 (17.1)
   Cardiac dysfunction (including previous history of coronary artery disease, cardiomyopathy, etc.)   11 (2.2)
  Site of primary                                                                                      
   Right sided                                                                                         273 (55.6)
   Left sided                                                                                          172 (35.1)
   Transverse colon                                                                                    30 (6.1)
   Epicentre not identifiable                                                                          16 (3.3)
   Mean nodes retrieved                                                                                22 (1-96)
  Histopathology                                                                                       
   PDAC                                                                                                132 (26.9)
   MDAC                                                                                                292 (59.5)
   WDAC                                                                                                15 (3.1)
   Adenocarcinoma, NOS                                                                                 52 (10.6)
  Mucinous histology                                                                                   
   Yes                                                                                                 90 (18.3)
   No                                                                                                  401 (81.7)
  Signet ring histology                                                                                
   Yes                                                                                                 40 (8.1)
   No                                                                                                  451 (91.9)
  Presence of perforation                                                                              
   Yes                                                                                                 17 (3.5)
   No                                                                                                  468 (95.3)
   Not available                                                                                       6 (1.2)
  Baseline obstruction                                                                                 
   Yes                                                                                                 122 (24.8)
   No                                                                                                  369 (75.2)
  Presence of lymphovascular emboli                                                                    
   Yes                                                                                                 113 (23.0)
   No                                                                                                  333 (67.8)
   Not available                                                                                       45 (9.2)
  Presence of perineural invasion                                                                      
   Yes                                                                                                 36 (7.3)
   No                                                                                                  179 (36.5)
   Not available                                                                                       276 (56.2)

PDAC=Poorly differentiated adenocarcinoma, MDAC=Moderately differentiated adenocarcinoma, WDAC=Well differentiated adenocarcinoma, NOS=Not otherwise specified

Adjuvant chemotherapy in Stage II cancers and in Stage III cancers {#sec2-5}
------------------------------------------------------------------

Details of chemotherapy administration in Stage II and Stage III are mentioned in Supplementary Tables [1](#T2){ref-type="table"} and [2](#T3){ref-type="table"}. Safety analysis and delivery of monotherapy and doublet adjuvant chemotherapy are described in [Table 2](#T4){ref-type="table"}. Patients with Stage I cancer were observed postresection.

###### 

Administration of adjuvant chemotherapy in stage II cancers (*n*=220)

  Characteristic                                                                 *n* (%)
  ------------------------------------------------------------------------------ -------------
  Adjuvant chemotherapy planned                                                  
   Yes                                                                           162 (3.6)
   No                                                                            58 (26.4)
  Reasons for lack of adjuvant chemotherapy (*n*=58)                             
   Age (years) \>70                                                              4 (6.9)
   MSI --H status with no clinicopathological poor prognostic factors            42 (72.4)
   Absence of clinicopathological poor prognostic factors with MSI -- S status   4 (6.9)
   Multiple uncontrolled comorbidities                                           1 (1.7)
   Patient choice                                                                4 (6.9)
   \>1 of factors 1--5                                                           3 (5.2)
  Regimens administered (*n*=162)                                                
   Monotherapy                                                                   68 (42.0)
    Capecitabine                                                                 65 (40.1)
    5 fluorouracil                                                               3 (1.9)
   Doublet chemotherapy                                                          94 (58.0)
    Capecitabine-oxaliplatin                                                     82 (50.6)
    5 fluorouracil -- oxaliplatin (FOLFOX-7)                                     12 (7.4)
  Completion of adjuvant chemotherapy (*n*=162)                                  
   Yes                                                                           138 (5.2)
   No                                                                            24 (14.8)
  Dose reduction during chemotherapy                                             
   Yes                                                                           27 (16.7)
   No                                                                            135 (83.3)
  Median no cycles of chemotherapy received                                      8 (1-12)
  Total number of doses of chemotherapy planned                                  1356 (100)
  Total number of doses of chemotherapy received                                 1177 (86.8)
  Reasons for premature cessation of planned adjuvant chemotherapy (*n*=24)      
   Grade 3 and Grade 4 toxicities                                                18 (75)
   Death during adjuvant chemotherapy                                            1 (4.2)
   Recurrence                                                                    1 (4.2)
   Lost to follow-up                                                             4 (16.6)

MSI=Microsatellite instability

###### 

Administration of adjuvant chemotherapy in stage III cancers (*n*=223)

  Characteristic                                                              *n* (%)
  --------------------------------------------------------------------------- -------------
  Adjuvant chemotherapy administered (*n*=218)                                
   Yes                                                                        215 (96.8)
   No                                                                         8 (3.2)
  Regimen planned (*n*=215)                                                   
   Monotherapy                                                                17 (7.9)
    Capecitabine                                                              14 (6.5)
    5 fluorouracil                                                            3 (1.4)
   Doublet chemotherapy                                                       198 (92.1)
    Capecitabine-oxaliplatin                                                  179 (83.3)
    5 fluorouracil -- oxaliplatin (FOLFOX-7)                                  19 (8.8)
  Completion of planned chemotherapy (*n*=215)                                
   Yes                                                                        180 (83.7)
   No                                                                         35 (16.3)
  Dose reduction during chemotherapy (*n*=215)                                
   Yes                                                                        29 (13.5)
   No                                                                         186 (86.5)
  Median number                                                               8 (1-12)
  Total number of doses of chemotherapy planned                               1808 (100)
  Total number of doses of chemotherapy received                              1624 (89.8)
  Reasons for premature cessation of planned adjuvant chemotherapy (*n*=35)   
   Grade 3 and Grade 4 toxicities                                             25 (71.4)
   Recurrence on adjuvant chemotherapy                                        4 (11.4)
   Patient death due to chemotherapy related complications                    1 (2.9)
   Lost to follow-up                                                          5 (14.3)

FOLFOX=5 Fluorouracil/Leucovorin/Oxaliplatin

###### 

Safety analysis and delivery of monotherapy and doublet adjuvant chemotherapy

  Adverse event                                          Single agent 5 fluorouracil/capecitabine (86)   Doublet FOLFOX-7/CAPOX (298)
  ------------------------------------------------------ ----------------------------------------------- ------------------------------
  Adverse events                                                                                         
   Febrile neutropenia                                   00                                              4 (1.3)
   Nonneutropenic infections                             1 (1.2)                                         8 (2.7)
   Neutropenia                                           00                                              4 (1.3)
   Thrombocytopenia                                      00                                              8 (2.7)
   HFS (Grade 2 and grade 3)                             22 (25.6)                                       60 (20.2)
   Vomiting                                              3 (3.5)                                         10 (3.3)
   mucositis                                             00                                              4 (1.3)
   Diarrhea                                              8 (9.3)                                         19 (6.4)
   Peripheral sensory neuropathy (Grade 2 and Grade 3)   4 (4.7)                                         46 (15.4)
   Death                                                 00                                              1 (0.3)
  Median number of cycles                                8 (1-12)                                        8 (1-12)
  Dose reduction required                                8 (9.3)                                         48 (16.1)
  Completed planned adjuvant                             73 (85)                                         242 (81.2)
  Total number of doses of chemotherapy planned          712 (100)                                       2508 (100)
  Total number of doses of chemotherapy received         636 (89.3)                                      2225 (88.7)

FOLFOX=5 Fluorouracil/Leucovorin/Oxaliplatin, CAPOX=Capecitabine-oxaliplatin, HFS=Hand-foot-syndrome

Two hundred and ninety-eight patients received doublet chemotherapy (modified CAPOX -- 266 patients; modified FOLFOX-7 -- 32 patients), whereas 86 patients received monotherapy (single-agent capecitabine -- 80 patients; single-agent 5-fluorouracil -- 6 patients).

Survival and prognostic factors {#sec2-6}
-------------------------------

With a median follow-up of 22 months, the median OS was not reached with an estimated 3-year OS of 93.6% for the entire cohort. The estimated 3-year OS of Stage I, Stage II and Stage III cancers was, 100%, 96.1%, and 88.9%, respectively \[[Figure 1](#F1){ref-type="fig"}\].

![Stage-wise overall survival](SAJC-8-160-g001){#F1}

Of the prognostic factors evaluated for OS, final stage, the degree of differentiation and younger age approached or attained statistical significance on univariate analysis. On multivariate analysis, Stage (*P* = 0.02) and younger age (*P* = 0.028) maintained statistical significance. Factors related to administration of adjuvant chemotherapy and predicting for inferior estimated 3-year OS included the presence of underlying cardiovascular abnormalities (*P* = 0.023), need for dose reductions (*P* = 0.038), and noncompletion of planned chemotherapy (\<0.001) \[[Table 3](#T5){ref-type="table"}\].

###### 

Univariate and multivariate analysis of significant prognostic and predictive factors for overall survival

  Characteristic                                  3 years OS   *P* (univariate analysis)   *P* (multivariate analysis)   HR (95% CI)
  ----------------------------------------------- ------------ --------------------------- ----------------------------- ---------------------
  Prognostic factors                                                                                                     
   Stage (%)                                                                                                             
    I                                             100          0.050                       0.020                         2.43 (1.147-5.141)
    II                                            96.1                                                                   
    III                                           88.9                                                                   
   Age (years) (%)                                                                                                       
    \<50                                          91.2         0.030                       0.028                         0.331 (0.123-0.89)
    ≥50                                           96.8                                                                   
  Predictive factors                                                                                                     
   Presence of cardiovascular comorbidities (%)                                                                          
    Yes                                           88.1         0.016                       0.023                         2.555 (1.140-5.725)
    No                                            95.6                                                                   
  Completion of chemotherapy (%)                                                                                         
    Yes                                           93.3         0.006                       \<0.001                       3.067 (1.675-5.617)
    No                                            82.7                                                                   
  Dose reduction (%)                                                                                                     
    Yes                                           75.3         0.013                       0.038                         0.629 (0.406-0.975)
    No                                            95.7                                                                   

HR=Hazard ratio, CI=Confidence interval, OS=Overall survival

A total of 49 events had occurred at median follow-up. The estimated 3 year EFS for Stage I, Stage II, and Stage III was 89.9%, 88.5%, and 75.7%, respectively \[[Figure 2](#F2){ref-type="fig"}\]. Three years estimated EFS for the entire cohort was 86%.

![Stage-wise event-free survival stage wise](SAJC-8-160-g002){#F2}

Of the prognostic factors evaluated for EFS, final stage, signet-ring morphology, and mucinous histology attained statistical significance on univariate analysis. On multivariate analysis, only final stage retained statistical significance for EFS (*P* = 0.022).

Discussion {#sec1-4}
==========

The importance of complete mesocolic excision aiming at the separation of the mesocolic from the parietal plane and true central ligation of the supplying vessels right at their roots has now been routinely adopted across centers and is used as standard in our institution.\[[@ref9][@ref23]\] The use of adjuvant chemotherapy, initially with 5-fluorouracil-based bolus regimens, and later with better tolerated infusional 5-fluorouracil -- oxaliplatin doublets, has additionally improved outcomes in Stage II and Stage III colon cancers.\[[@ref10][@ref11][@ref12][@ref13][@ref24][@ref25]\] Such has been the improvement in outcomes that there is a trend toward a reductionist approach regarding duration and regimen of adjuvant therapy. The IDEA project, comprising more than 12,000 patients from six pooled trials has offered patients and treating physicians the options of 3 months of therapy in Stage III cancers.\[[@ref19]\]

Data from India regarding incidence, prevalence, and outcomes of CRC is scarce.\[[@ref2][@ref20]\] In the current study baseline characteristics which appear different in as compared to published literature include a younger median age of presentation (sixth decade as opposed to seventh in western studies), a relatively smaller proportion of elderly patients (16.2%), and a higher percentage of signet-ring histology (8.1%).\[[@ref13][@ref26][@ref27]\]

About 26.4% of patients with Stage II cancers did not receive adjuvant chemotherapy. Of the remaining 73.6% of patients, a majority received a doublet regimen. These patterns are reflective of the unsolved questions of whether MSI status trumps traditional poor prognostic factors, the lack of benefit of 5 FU/capecitabine in MSI-H tumors and the potential for oxaliplatin to overcome lack of benefit of 5-FU in MSI-H tumors.\[[@ref28][@ref29][@ref30][@ref31]\] Stage II tumors are a heterogeneous cohort, with treatment decisions being individualized. A patient with a T4 disease (25.9% in this subset of Stage II cancers) and poorly differentiated histology, but Stage II is likely to behave closer to a Stage III cohort (with potential benefit from a doublet adjuvant regimen) in terms of outcomes as opposed to a patient with T3 disease, MSI -- H status and lack of poor prognostic factors (likely candidate for observation).

Patients with Stage III disease were mostly treated with either CAPOX or mFOLFOX-6 regimens (92.1%), as is currently recommended by guidelines.\[[@ref29]\] Despite being a real-world nontrial cohort, completion rates with adjuvant doublet regimens in this study in Stage III cancers were an impressive 83.7%, as opposed to lower rates seen in international seminal studies (André *et al.*, FOLFOX -- 74.7%; Haller *et al.*, CAPOX -- 69%).\[[@ref12][@ref32]\] 89.8% of doses of all planned chemotherapy was delivered. This is a pointer toward careful patient selection required for administration of adjuvant chemotherapy as well as the use of a lower dose of capecitabine (2000 mg/m^2^/day as opposed to 2500 mg/m^2^/day).

Compliance and completion rates with adjuvant chemotherapy in this study were high and this is heartening to note. Eighty-five percent and 81.2% of patients receiving monotherapy and doublet chemotherapy, respectively, were able to complete their planned 6 months of adjuvant treatment. Toxicities seen with monotherapy were mainly hand-foot-syndrome (HFS: Grade 2 and Grade 3%--25.6%) and diarrhea (9.5%), while with oxaliplatin-based doublet, sensory peripheral neuropathy was the most common dose-limiting toxicity (Grade 2 and Grade 3%--14.5%), though incidence of HFS was also high (20.2%). The incidence of neuropathy is similar to published literature, but also is a cautionary note with regard to the need for constant surveillance while on oxaliplatin. The short follow-up duration of this study means we are unable to comment on the incidence of long-term residual neuropathy, which may be irreversible and range anywhere between 10% and 79%.\[[@ref11][@ref13][@ref33]\] The incidence of myelosuppression-related side-effects was low in this study. While the incidence of myelosuppression across studies has been low with FOLFOX/CAPOX across regimens in published literature, an additional reason for this low incidence in this study is the use of modified FOLFOX-7 regimen (no bolus 5-FU) as adjuvant chemotherapy in our institution.

Due to the lower age incidence of CRC in India, there is a surfeit of data regarding the survival and use of adjuvant chemotherapy in elderly patients (\>65 years).\[[@ref34][@ref35][@ref36]\] 16.5% of patients in this study were elderly, and they had a stage-wise distribution that mirrored the entire cohort. We also noted a lower incidence of signet and mucinous CRC in the elderly population as compared to the entire cohort and this difference was statistically significant for both characteristics (not shown). Completion rates of adjuvant chemotherapy were 76.3% for the elderly population, and this was nearly 10% less than completion rates for the entire cohort. This highlights the need for careful patient selection as well as the potentially similar benefit elderly patients derive from fully-dosed adjuvant chemotherapy as compared to a younger population.

There have been increasing data evaluating the correlation of outcomes with completion rates of adjuvant chemotherapy, lower completion rates of chemotherapy in an elderly population as well as the presence of comorbidities like diabetes mellitus being associated with poorer survival in CRC.\[[@ref36][@ref37][@ref38][@ref39]\] The high burden of cardiovascular comorbidities in the Indian population is reflected in our study and enabled us to evaluate whether such comorbidities affect outcomes (diabetes mellitus -- 17.1%, hypertension -- 18.9%).\[[@ref40]\] Despite the short follow in this study, patients who had comorbidities required dose reduction and were unable to complete planned chemotherapy clearly had an inferior survival. The recently published ACCORE study also had identified a cohort of elderly patients receiving \<50% of planned cycles of chemotherapy as having an inferior survival.\[[@ref36]\] The conundrum of whether patients with comorbidities receive lesser dose intensity to avoid toxicities as opposed to uncontrolled comorbidities affecting the delivery of maintained intensity of chemotherapy is a common problem to tackle for treating physicians.

The short follow-up and lack of events in this study preclude a detailed analysis of outcomes and prognostic factors. Early outcomes in all stages of colon cancer in this cohort appear satisfactory with very low recurrence rates. A longer follow-up will enable a more accurate picture of actual survival and outcomes. Besides stage, the only factor associated with inferior OS was a younger age group (\<50 years). Such a correlation between age and inferior outcomes in CRC has been seen in previous Indian and Chinese studies, though at various age cut-offs.\[[@ref2][@ref41][@ref42]\] While overall initial outcomes for all cohorts in this study appear high, the inferior survival in a younger age group merits further evaluation.\[[@ref43]\]

The current study is the first of its kind from India and gives a snapshot of the practice of adjuvant chemotherapy and compliance with the same in a purely nonmetastatic colon cancer cohort. We have also identified certain practice-related factors like the need for dose reduction and the presence of comorbidities influencing outcomes adversely. However, multiple caveats exist, considering this is a retrospective study. MSI status is not reported in all stages and we have concentrated only on Grade 3 and Grade 4 side effects in reporting toxicities. We have also not reported as to why patients were treated with 5-fluorouracil versus capecitabine-based regimens despite treatment in a single center. Most importantly, the short median follow-up of 22 months precludes any firm judgment on the survival outcomes of Indian patients as compared to those from other countries where colon cancers are more common.

Conclusions {#sec1-5}
===========

The current study identifies a lower age of presentation of non-- metastatic colon cancers in India, with high compliance and completion rates of planned adjuvant chemotherapy. Early survival outcomes appear comparable to published literature, but longer follow-up is required. Stage and younger ages (\<50 years) were prognostic, while the presence of cardiovascular comorbidities, and inability to administer planned chemotherapy due to dose reduction and premature cessation, appear to affect survival adversely.
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